SHLP-2 Reference

Plain English

What it is

SHLP-2 (short for small humanin-like peptide 2) is a research peptide that the body naturally makes inside mitochondria, the tiny power plants in our cells. It is a lesser-known relative of two other mitochondrial peptides, humanin and MOTS-c. It is sold only as a research chemical and is not an approved medicine.

What people use it for

In the peptide community it is talked about for metabolism, blood sugar handling (insulin sensitivity), eye health, and general anti-aging or longevity. These are hopes drawn from early lab work, not approved or proven uses.

What the science shows

Almost all of the evidence comes from mice and from human cells grown in a dish, not from people. In those lab studies it protected mice from diet-driven weight gain and improved their insulin sensitivity, and it protected human retinal cells in a macular-degeneration model. There are no human studies testing whether it actually works.

The catch

There is no FDA-approved SHLP-2 product and no human intervention data at all, so the longevity, fat-loss, and metabolic claims stay unproven in people. Because it has never been tested in human trials, its safety in people is unknown.

Reference summary

Mouse and cell-model literature suggests roles in energy homeostasis, insulin sensitivity, oxidative stress, and retinal / macular-degeneration models. Human intervention data are absent.

Regulatory and posture

Categories

Longevity, Metabolic

Aliases

Small humanin-like peptide 2, SHLP2, Mitochondrial-derived peptide

Evidence posture

preclinical - Preclinical mitochondrial-derived peptide. Longevity, fat-loss, and metabolic claims are unproven in humans.

Regulatory status

No FDA-approved SHLP-2 drug label. SHLP-2 is a mitochondrial-derived peptide studied in preclinical metabolic, aging, oxidative-stress, and eye-disease models.

Content review status

research reference

Related tools

• Injection-site rotation overview - Public overview of the Pro site-rotation planner.